Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole and D-Cycloserine in Autism
NCT00198107Phase 3Completed
- Sponsor
- Indiana University
- Start
- Sep 2005
- Primary completion
- Sep 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Placebo, Aripiprazole and Aripiprazole + D-cycloserine (3 arms). Primary endpoints: Aberrant Behavior Checklist Irritability Score at 8 weeks and Clinical Global Impression-Global Improvement Scale at 8 weeks. Started Sep 2005; status: completed.
02
Drugs
aripiprazoled-cycloserine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00198107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198107.